Coenzyme Q10 dose-escalation study in hemodialysis patients: Safety, tolerability, and effect on oxidative stress Dialysis and Transplantation

BMC Nephrology

Volumn 16, Issue 1, 2015, Pages

  Yeung, Catherine K ^a,b   Billings, Frederic T ^c   Claessens, Adam J ^a   Roshanravan, Baback ^b   Linke, Lori ^b   Sundell, Mary B ^c   Ahmad, Suhail ^b   Shao, Baohai ^a   Shen, Danny D ^a   Ikizler, T Alp ^c   Himmelfarb, Jonathan ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical study; Coenzyme Q10; Hemodialysis; Kidney disease; Oxidative stress

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; ICOSANOID; INTERLEUKIN 6; ISOFURAN DERIVATIVE; ISOPROSTANE DERIVATIVE; UBIDECARENONE; UNCLASSIFIED DRUG; UBIQUINONE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; IN VIVO STUDY; MALE; MYALGIA; NAUSEA; OXIDATIVE STRESS; PATIENT SAFETY; PROTEIN BLOOD LEVEL; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIETARY SUPPLEMENT; DRUG EFFECTS; DRUG TOLERANCE; KIDNEY FAILURE, CHRONIC; MAXIMUM ALLOWABLE CONCENTRATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; UBIQUINONE; UNITED STATES; YOUNG ADULT;

EID: 84959196127     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-015-0178-2     Document Type: Article

References (27)

1. U S Renal Data System, USRDS. Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013. www.usrds.org.
2. MEDPAC. A Data Book: Healthcare Spending and the Medicare Program. 2009.
3. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48(5):752-60. doi: 10.1053/j.ajkd.2006.08.015.
4. Kuchta A, Pacanis A, Kortas-Stempak B, Cwiklinska A, Zietkiewicz M, Renke M, et al. Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res. 2011;34(1):12-9. doi: 10.1159/000321508.
5. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton). 2012;17(4):311-21. doi: 10.1111/j.1440-1797.2012.01572.x.
6. Beyer RE. The participation of coenzyme Q in free radical production and antioxidation. Free Radic Biol Med. 1990;8(6):545-65.
7. Kandar R. The ratio of oxidized and reduced forms of selected antioxidants as a possible marker of oxidative stress in humans. Biomed Chromatogr. 2015. doi: 10.1002/bmc.3529.
8. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62(5):1524-38. doi: 10.1046/j.1523-1755.2002.00600.x.
9. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol. 2008;19(3):593-9. doi: 10.1681/ASN.2007030355.
10. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med. 2005;38(6):698-710. doi: 10.1016/j.freeradbiomed.2004.09.017.
11. Fessel JP, Hulette C, Powell S, Roberts 2nd LJ, Zhang J. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem. 2003;85(3):645-50.
12. Fessel JP, Porter NA, Moore KP, Sheller JR, Roberts 2nd LJ. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci U S A. 2002;99(26):16713-8. doi: 10.1073/pnas.252649099.
13. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int. 2001;59(5):1960-6. doi: 10.1046/j.1523-1755.2001.0590051960.x.
14. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol. 2002;58(3):190-7.
15. Claessens AJ, Yeung CK, Risler LJ, Phillips BR, Himmelfarb J, Shen DD. Rapid and sensitive analysis of reduced and oxidized coenzyme Q10 in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and application to studies in healthy human subjects. Ann Clin Biochem. 2015.
16. Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc. 2007;2(1):221-6. doi: 10.1038/nprot.2006.375.
17. Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A. 2008;105(34):12224-9. doi: 10.1073/pnas.08020251050802025105.
18. Billings FT 4th. Intraoperative normoxia, oxidative damage, and organ injury following cardiac surgery. Shock. 2015;43(S1):24.
19. Babb AL, Ahmad S, Bergstrom J, Scribner BH. The middle molecule hypothesis in perspective. Am J Kidney Dis. 1981;1(1):46-50.
20. Sakata T, Furuya R, Shimazu T, Odamaki M, Ohkawa S, Kumagai H. Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif. 2008;26(4):371-8. doi: 10.1159/000135605.
21. Singh RB, Kumar A, Niaz MA, Singh RG, Gujrati S, Singh VP, et al. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in patients with End-stage renal failure. J Nutr Environ Med. 2003;13(1):13-22.
22. Milne GL, Gao B, Terry ES, Zackert WE, Sanchez SC. Measurement of F2- isoprostanes and isofurans using gas chromatography-mass spectrometry. Free Radic Biol Med. 2013;59:36-44. doi: 10.1016/j.freeradbiomed.2012.09.030.
23. Shao B, Heinecke JW. Using tandem mass spectrometry to quantify site-specific chlorination and nitration of proteins: model system studies with high-density lipoprotein oxidized by myeloperoxidase. Methods Enzymol. 2008;440:33-63. doi: 10.1016/S0076-6879(07)00803-8.
24. von Eckardstein A, Walter M, Holz H, Benninghoven A, Assmann G. Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III. J Lipid Res. 1991;32(9):1465-76.
25. Kamimura MA, Draibe SA, Dalboni MA, Cendoroglo M, Avesani CM, Manfredi SR, et al. Serum and cellular interleukin-6 in haemodialysis patients: relationship with energy expenditure. Nephrol Dial Transplant. 2007;22(3):839-44.
26. Baskaran R, Shanmugam S, Nagayya-Sriraman S, Kim JH, Jeong TC, Yong CS, et al. The effect of coenzyme Q10 on the pharmacokinetic parameters of theophylline. Arch Pharm Res. 2008;31(7):938-44. doi: 10.1007/s12272-001-1250-1.
27. Itagaki S, Ochiai A, Kobayashi M, Sugawara M, Hirano T, Iseki K. Interaction of coenzyme Q10 with the intestinal drug transporter P-glycoprotein. J Agric Food Chem. 2008;56(16):6923-7. doi: 10.1021/jf800992p.